Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Albert Bourla, the CEO of pharmaceutical company Pfizer ($PFE), plans to meet with activist investor Starboard Value in ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV ...

Pfizer Inc has inaugurated its first commercial analytics centre in Mumbai, India. This global capability centre will serve Pfizer's international markets outside the US, employing data analytics ...

Some Pfizer investors are hungry for an encore and showing their displeasure by shunning the stock. The attitude has left the shares undervalued, in the opinion of one pundit (and his bullish view ...

Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. Pfizer’s oncology chief has warned that the Biden administration’s drug price reforms could hurt ...